Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Venetoclax + Lenalidomide + Rituximab Hyaluronidase in Relapsed or Refractory (R/R) Indolent Non-Hodgkin's Lymphoma (iNHL).

NCT04447716 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT04447716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04447716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Venetoclax + Lenalidomide + Rituximab Hyaluronidase in Relapsed or Refractory (R/R) Indolent Non-Hodgkin's Lymphoma (iNHL).
Lead sponsor
Thomas Jefferson University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 16, 2020
Completion date
March 31, 2027
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell non-hodgkin lymphoma, recurrent follicular lymphoma, recurrent indolent adult non-hodgkin lymphoma, recurrent marginal zone lymphoma, refractory b-cell non-hodgkin lymphoma, refractory follicular lymphoma, refractory indolent adult non-hodgkin lymphoma, refractory marginal zone lymphoma